Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant-activated coagulation factor VIIa (NovoSeven): current development.

R B Weiskopf1

  • 1Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd, Denmark. rwes@novonordisk.com

Vox Sanguinis
|April 26, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ethics of blood management.

Vox sanguinis·2007
Same author

Assessment of hemostasis through the retrospectroscope.

Journal of thrombosis and haemostasis : JTH·2006
Same author

Efficacy of acute normovolemic hemodilution assessed as a function of fraction of blood volume lost.

Anesthesiology·2001
Same author

Electrocardiographic ST-segment changes during acute, severe isovolemic hemodilution in humans.

Anesthesiology·2000
Same author

Erythrocyte salvage during cesarean section.

Anesthesiology·2000
Same author

Acute severe isovolemic anemia impairs cognitive function and memory in humans.

Anesthesiology·2000
Same journal

Red cell alloantibodies in 71,525 Malaysian blood donations: Predominance of anti-Mia reflects GP.Mur-associated antigenic diversity.

Vox sanguinis·2026
Same journal

Barriers and enablers to non-remunerated plasma donation: A meta-synthesis of the qualitative literature using the theoretical domains framework.

Vox sanguinis·2026
Same journal

Haemolytic disease of the foetus and newborn due to anti-M: A systematic review.

Vox sanguinis·2026
Same journal

In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.

Vox sanguinis·2026
Same journal

Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiency.

Vox sanguinis·2026
Same journal

Fibrinogen recovery in cryoprecipitate prepared from thawed plasma stored for 5 days post-thaw.

Vox sanguinis·2026
See all related articles

Recombinant activated coagulation factor VII (rFVIIa) shows promise beyond hemophilia treatment. This review focuses on its efficacy and safety in other bleeding conditions based on clinical trials.

Area of Science:

  • Hematology
  • Pharmacology
  • Clinical Trials

Background:

  • Recombinant activated coagulation factor VII (rFVIIa) was initially developed for hemophilia patients with inhibitors.
  • Its unique mechanism of action prompted investigation for other hemostatic challenges.

Purpose of the Study:

  • To review the development of rFVIIa for non-hemophilia indications.
  • To summarize findings from prospective, randomized clinical trials.

Main Methods:

  • Focus on prospective, randomized clinical trials.
  • Evaluation of efficacy and safety data.

Main Results:

  • Summarizes current development of rFVIIa.
  • Highlights clinical trial outcomes for broader applications.

Related Experiment Videos

Conclusions:

  • rFVIIa is being explored for various hemostatic conditions.
  • Clinical trial data guides its expanded therapeutic use.